Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373525 | 0.92 | NAMPT (0.47) | NAMPTHDAC1PIP4K2CPIP4K2APIP4K2B | |
| SCHEMBL1244787 | 0.91 | PIP4K2C (0.44) | PIP4K2CPDGFRAKITPIP4K2APIP4K2B | |
| SCHEMBL1244498 | 0.88 | KIT (0.48) | PIP4K2CPDGFRAKITPIP4K2APIP4K2B | |
| SCHEMBL4386977 | 0.86 | PIP4K2A (0.42) | PIP4K2CPDGFRAKITPIP4K2APIP4K2B | |
| SCHEMBL4376216 | 0.86 | PIP4K2C (0.44) | NAMPTHDAC1PIP4K2CPIP4K2APIP4K2B | |
| SCHEMBL4378674 | 0.85 | PIP4K2C (0.41) | NAMPTPIP4K2CPIP4K2APIP4K2BPIKFYVE | |
| SCHEMBL4375738 | 0.85 | PIP4K2C (0.47) | NAMPTHDAC1PIP4K2CPIP4K2APIP4K2B | |
| Trifluoroacetic Acid SCHEMBL1244403 | 0.85 | KIT (0.44) | PIP4K2CPDGFRAKITPIP4K2APIP4K2B | |
| SCHEMBL4371520 | 0.85 | PIP4K2C (0.44) | NAMPTPIP4K2CPIP4K2APIP4K2BMAPT | |
| SCHEMBL4375782 | 0.85 | PIP4K2C (0.54) | NAMPTPIP4K2CPIP4K2APIP4K2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | NAMPT 455/4885HDAC1 130/4885PIP4K2C 4147/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | NAMPT 679/4885HDAC1 246/4885PIP4K2C 3538/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | NAMPT 455/4885HDAC1 130/4885PIP4K2C 4147/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | NAMPT 1393/4885HDAC1 3475/4885PIP4K2C 4240/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | NAMPT 679/4885HDAC1 246/4885PIP4K2C 3538/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | NAMPT 679/4885HDAC1 189/4885PIP4K2C 4198/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | NAMPT 455/4885HDAC1 130/4885PIP4K2C 4147/4885 |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | NAMPT 679/4885HDAC1 189/4885PIP4K2C 4198/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | NAMPT 455/4885HDAC1 130/4885PIP4K2C 4147/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | NAMPT 679/4885HDAC1 189/4885PIP4K2C 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.